Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences

Prostate

Volumn 48, Issue 1, 2001, Pages 29-39

  Collette, Laurence ^a   Studer, Urs E ^b   Schröder, Fritz H ^c   Denis, Louis J ^d   Sylvester, Richard J ^a  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY OF BERN   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Oncology Centre of Antwerp   (Belgium)

Author keywords

Maximal androgen blockade; Metastatic prostate cancer; Statistical design

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ARTICLE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANILIDES; CLINICAL TRIALS, PHASE III; CYPROTERONE ACETATE; FACTOR ANALYSIS, STATISTICAL; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; LEUPROLIDE; MALE; META-ANALYSIS; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035876032     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1078     Document Type: Article

References (29)

1. New hormonal therapy in prostatic carcinoma: Combined treatment with an LH-RH agonist and an anti-androgen
2. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths and 5710 patients
3. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials
4. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
5. Leuprolide with or without flutamide in advanced prostate cancer
6. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853)
7. Goserilin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
8. Maximal androgen blockade: Final analysis of EORTC phase III trial 30853
9. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer
10. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
11. Does maximal androgen blockade (MAB) improve survival?
12. Arguments against the long-term use of combined androgen blockade
13. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials
14. Prognostic factors in stage D2 prostate cancer: Important implications for future trials: Results of a cooperative intergroup study (int 0036)
15. Some statistical considerations for the interpretation of trials of combined androgen therapy
16. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 occurrences and 24,000 deaths among 75,000 women
17. A reversal of fortune: Practical problems in the monitoring and interpretation of an EORTC breast cancer trial
18. Combined androgen blockade for the treatment of metastatic prostate cancer
19. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: The argument against
20. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
21. Hormonal manipulation of prostatic cancer. Too soon for total androgen blockade?
22. Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma
23. Maximum androgen blockade in 1996
24. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer
25. Complete androgen blockade for prostate cancer: What went wrong?
26. Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial
27. Advanced prostate cancer. The role of high priced hormone therapy
28. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer
29. Assessing the economic value of anticancer therapies